Real-world Health Outcomes in Canadian Patients Using Semaglutide

Sponsor
LMC Diabetes & Endocrinology Ltd.
Study ID
NCT04175665
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    Prescription for semaglutide as part of usual clinical practice

Study Details

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are an injectable, non-insulin therapy for patients with type 2 diabetes (T2D). Semaglutide (Ozempic®) is the newest GLP-1 RA to become available in Canada in 2018, and is administered subcutaneously once-weekly. In clinical trials, semaglutide has been superior to placebo and other antihyperglycemic agents in HbA1c reduction and body weight loss. However, there is little real-world evidence available on the effectiveness of semaglutide in real-world clinical practice. To better understand the effectiveness of semaglutide on clinical outcomes in a real-world setting, this retrospective cohort study will use the Canadian LMC Diabetes Registry to examine the effects of semaglutide on glycemic control, body weight, and other clinical outcomes in patients with T2D who initiate once-weekly semaglutide as part of usual clinical care in a diabetes specialist practice group in Canada.

Key Dates

Start date
Jan 6, 2020
Status verified
Feb 2020
Primary completion
Feb 9, 2020
Completion
Feb 9, 2020

Study Design

Enrollment
1,133 participants (actual)

Primary Outcome Measure

Change in HbA1c [ Time Frame: 3 to 6 months ]

Related Studies